ESTRO 2025 - Abstract Book

S1778

Clinical – Upper GI

ESTRO 2025

up visit in five categories: very good, good, average, poor and very poor, and the analyses were dichotomized into “not poor” and “poor health”. Data on demographic and disease characteristics were also analyzed.

Results: The male to female rate was 3.5:1. Gastric cancer patients included in the study was 59.8 years old (range 26-86). Upon multivariable adjustment for all covariates, demographic factor affecting self-perceived health in gastric cancer patients were age, sex, educational level, employment status, (p<0.001) and living in urban vs rural area (p< 0.0001). Poor self-perceived health in gastric cancer was with male sex, (OR=1.7, 95%CI=1.5-1.9), under 55 years old (OR=1.6, 95%CI=1.4-1.9) and university education level (OR=1.3, 95%CI=1.4-1.5). Disease and treatment related factors affecting self-perceived health in gastric cancer patients were type of surgery, adjuvant treatment, presence of R1 margins (p=0.001) and treatment toxicity (p< 0.0001). Significant correlates of poor self-perceived health in gastric cancer patients were in post total gastrectomy (OR=1.5, 95%CI=1.3-1.7), neoadjuvant chemotherapy (OR=1.7, 95%CI=1.6-1.9), adjuvant concomitant treatment (OR=1.3, 95%CI=1.1-1.5), presence of R1 margins (OR=1.8, 95%CI=1.6-2.1) and presence of treatment toxicity (OR=2, 95%CI=1.9- 2.2). Conclusion: This study is the first to explore perceived health among gastric cancer patients. Our findings reveal a significant association between self-perceived health and both demographic and disease related factors. Therefore, these factors should be considered in the interventions to improve the SPH of gastric cancer patients. Digital Poster Clinical and dosimetric outcomes of Stereotactic MR-guided adaptive radiotherapy (SMART) reirradiation for Liver Metastases Elena Moreno-Olmedo 1,2 , Kasia Owczarczyk 3 , Dan Murray 1 , Ben George 1 , Andy Gaya 1 , Veni Ezhil 1 , Ramanivas Sundareyan 4 , Somnath Mukherjee 1 , Peter Dickinson 1 , James Good 1 1 Stereotactic and MR-guided Radiotherapy, GenesisCare UK, Oxford, United Kingdom. 2 Radiotherapy and Oncology, Oxford University Hospitals (OUH)NHS Foundation Trust, Oxford, United Kingdom. 3 Stereotactic and MR-guided Radiotherapy, GenesisCare UK, London, United Kingdom. 4 Radiology, GenesisCare UK, London, United Kingdom Purpose/Objective: Stereotactic ablative body radiotherapy (SABR) is a well-established non-invasive local treatment for liver metastases, achieving high local control (LC). However, up to 50% of patients experience intra-hepatic progression 1 . Limited data exist on repeated liver SABR. Stereotactic MR-guided radiotherapy (SMART) is an optimal approach for delivering treatment in the upper abdomen 2,3 . This study evaluates the SMART reirradiation benefits for liver metastases. Material/Methods: SABR re-irradiation of liver metastases delivered with SMART were included in this single-centre retrospective analysis. Reirradiation criteria included ≤ four metastases without tumour size limit, uninvolved liver volume ≥ 700cc and Child-Pugh score ≤ B7. Treatment intent was classified according to the ESTRO-EORTC reirradiation and oligometastatic consensus 4,5 . Acute and late toxicities (CTCAEv5.0), LC, progression-free-survival (PFS), and overall survival (OS) were evaluated. Results: Between October/2020-April/2024, twelve patients received SMART reirradiation for 18 lesions (66,7% from colorectal-cancer). 75% had received primary liver-SMART and 58.3% prior additional liver-directed-treatment Keywords: Self perceived health, gastric cancer, well-being 1780